{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:16:33Z","timestamp":1773364593219,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Miller Fisher syndrome (MFS) is a subtype of Guillain-Barr\u00e9 syndrome (GBS) which is characterized by the three components of ophthalmoplegia, ataxia, and areflexia. Some studies reported MFS as an adverse effect of the COVID-19 vaccination. We aimed to have a detailed evaluation on demographic, clinical, and para-clinical characteristics of subjects with MFS after receiving COVID-19 vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A thorough search strategy was designed, and PubMed, Web of Science, and Embase were searched to find relevant articles. Each screening step was done by twice, and in case of disagreement, another author was consulted. Data on different characteristics of the patients and types of the vaccines were extracted. The risk of bias of the studies was assessed using Joanna Briggs Institute (JBI) tools.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In this study, 15 patients were identified from 15 case studies. The median age of the patients was 64, ranging from 24 to 84 years. Ten patients (66.6%) were men and Pfizer made up 46.7% of the injected vaccines. The median time from vaccination to symptoms onset was 14 days and varied from 7 to 35 days. Furthermore,14 patients had ocular signs, and 78.3% (11\/14) of ocular manifestations were bilateral. Among neurological conditions, other than MFS triad, facial weakness or facial nerve palsy was the most frequently reported side effect that was in seven (46.7%) subjects. Intravenous immunoglobulin (IVIg) was the most frequently used treatment (13\/15, 86.7%). Six patients received 0.4 g\/kg and the four had 2 g\/kg. Patients stayed at the hospital from five to 51 days. No fatal outcomes were reported. Finally, 40.0% (4\/15) of patients completely recovered, and the rest experienced improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MFS after COVID-19 immunization has favorable outcomes and good prognosis. However, long interval from disease presentation to treatment in some studies indicates that more attention should be paid to MFS as the adverse effect of the vaccination. Due to the challenging diagnosis, MFS must be considered in list of the differential diagnosis in patients with a history of recent COVID-19 vaccination and any of the ocular complaints, ataxia, or loss of reflexes, specially for male patients in their 60s and 70s.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-023-03375-4","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T07:02:52Z","timestamp":1695279772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics and prognosis of temporary miller fisher syndrome following COVID-19 vaccination: a systematic review of case studies"],"prefix":"10.1186","volume":"23","author":[{"given":"Dorsa","family":"Alijanzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Afra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fardis","family":"Salmanpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hossein","family":"Loghman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noosha","family":"Samieefar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"issue":"2","key":"3375_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJM195607122550201","volume":"255","author":"M Fisher","year":"1956","unstructured":"Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57\u201365.","journal-title":"N Engl J Med"},{"issue":"1","key":"3375_CR2","first-page":"57","volume":"12","author":"P Berlit","year":"1992","unstructured":"Berlit P, Rakicky J. The Miller Fisher syndrome. Review of the literature. J Clin Neuro-ophthalmol. 1992;12(1):57\u201363.","journal-title":"J Clin Neuro-ophthalmol"},{"issue":"4","key":"3375_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/WNO.0b013e3181c2514b","volume":"29","author":"LA Snyder","year":"2009","unstructured":"Snyder LA, Rismondo V, Miller NR. The Fisher variant of Guillain-Barr\u00e9 syndrome (Fisher syndrome). J Neuroophthalmol. 2009;29(4):312\u201324.","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"3375_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1212\/WNL.57.4.686","volume":"57","author":"M Koga","year":"2001","unstructured":"Koga M, Yuki N, Tai T, Hirata K. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology. 2001;57(4):686\u201391.","journal-title":"Neurology"},{"issue":"4","key":"3375_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jamda.2008.01.013","volume":"9","author":"A Thaler","year":"2008","unstructured":"Thaler A. Miller Fisher syndrome in a 66-year-old female after flu and pneumovax vaccinations. J Am Med Dir Assoc. 2008;9(4):283\u20134.","journal-title":"J Am Med Dir Assoc"},{"issue":"10","key":"3375_CR6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/archneurol.2011.236","volume":"68","author":"A Shoamanesh","year":"2011","unstructured":"Shoamanesh A, Chapman K, Traboulsee A. Postvaccination miller Fisher syndrome. Arch Neurol. 2011;68(10):1327\u20139.","journal-title":"Arch Neurol"},{"issue":"5","key":"3375_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jinf.2012.11.014","volume":"66","author":"HH Kr\u00e4mer","year":"2013","unstructured":"Kr\u00e4mer HH, Niem\u00f6ller U, D\u00f6ring K, Fockenberg S, Kaps M, Nedelmann M. Postvaccination Miller Fisher syndrome after combined pertussis, diphtheria and tetanus toxoid vaccine. J Infect. 2013;66(5):460\u20131.","journal-title":"J Infect"},{"issue":"24","key":"3375_CR8","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung H-P. Guillain\u2013barr\u00e9 syndrome. N Engl J Med. 2012;366(24):2294\u2013304.","journal-title":"N Engl J Med"},{"key":"3375_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.puhe.2021.07.037","volume":"198","author":"K Jab\u0142o\u0144ska","year":"2021","unstructured":"Jab\u0142o\u0144ska K, Aball\u00e9a S, Toumi M. The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. Public Health. 2021;198:230\u20137.","journal-title":"Public Health"},{"key":"3375_CR10","doi-asserted-by":"publisher","unstructured":"Garg RA-O, Paliwal VA-O. Spectrum of neurological complications following COVID-19 vaccination. 2022;43(1):3\u201340. https:\/\/doi.org\/10.1007\/s10072-021-05662-9.","DOI":"10.1007\/s10072-021-05662-9"},{"key":"3375_CR11","doi-asserted-by":"publisher","unstructured":"Patone M, Handunnetthi LA-O, Saatci D, Pan J, Katikireddi SA-O, Razvi SA-OX, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. 2021;27(12):2144\u201353. https:\/\/doi.org\/10.1038\/s41591-021-01556-7.","DOI":"10.1038\/s41591-021-01556-7"},{"issue":"5","key":"3375_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ana.26065","volume":"89","author":"AL Goss","year":"2021","unstructured":"Goss AL, Samudralwar RD, Das RR, Nath A. ANA Investigates: Neurological Complications of COVID-19 Vaccines. Ann Neurol. 2021;89(5):856\u20137.","journal-title":"Ann Neurol"},{"key":"3375_CR13","doi-asserted-by":"crossref","unstructured":"Lee JR, Jaffry M, Mandava K, Rosario S, Elshourbagy T, Jaffry K, et al. Investigating the relationship of Miller Fisher Syndrome and COVID-19 Vaccination: A Vaccine Adverse Event Reporting (VAERS) Study (P4\u20139.001). Chicago: American Academy of Neurology; 2022.","DOI":"10.1212\/WNL.98.18_supplement.1499"},{"key":"3375_CR14","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"3375_CR15","doi-asserted-by":"crossref","unstructured":"Moola S MZ, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Currie M, Qureshi R, Mattis P, Lisy K, Mu P-F. Systematic reviews of etiology and risk. In: Aromataris E MZ, editor. JBI Manual for Evidence Synthesis: JBI. Adelaide: Faculty of Health and Medical Sciences; 2020.","DOI":"10.46658\/JBIRM-17-06"},{"key":"3375_CR16","doi-asserted-by":"publisher","unstructured":"Munn Z BT, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E. Methodological quality of case series studies. JBI Evidence Synthesis. 2020;18(10):2127\u201333. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","DOI":"10.11124\/JBISRIR-D-19-00099"},{"key":"3375_CR17","unstructured":"CRITICAL APPRAISAL TOOLS: Joanna Briggs Institute; [Available from: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"3375_CR18","doi-asserted-by":"publisher","unstructured":"Abi\u010di\u0107 A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurol Sci. 2022;43(3):1495-7. https:\/\/doi.org\/10.1007\/s10072-021-05776-0.","DOI":"10.1007\/s10072-021-05776-0"},{"issue":"11","key":"3375_CR19","doi-asserted-by":"publisher","first-page":"e246701","DOI":"10.1136\/bcr-2021-246701","volume":"14","author":"YL Dang","year":"2021","unstructured":"Dang YL, Bryson A. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination. BMJ Case Reports CP. 2021;14(11):e246701.","journal-title":"BMJ Case Reports CP"},{"key":"3375_CR20","doi-asserted-by":"publisher","unstructured":"Kubota T, Hasegawa T, Ikeda K, Aoki M. Case Report: Isolated, unilateral oculomotor palsy with anti-GQ1b antibody following COVID-19 vaccination. F1000Res. 2021;10:1142. https:\/\/doi.org\/10.12688\/f1000research.74299.2.","DOI":"10.12688\/f1000research.74299.2"},{"issue":"2","key":"3375_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/CND.0000000000000376","volume":"23","author":"NM Michaelson","year":"2021","unstructured":"Michaelson NM, Lam T, Malhotra A, Schiff ND, MacGowan DJL. Miller Fisher syndrome presenting after a second dose of Pfizer-BioNTech vaccination in a patient with resolved COVID-19: a case report. J Clin Neuromuscul Dis. 2021;23(2):113\u20135.","journal-title":"J Clin Neuromuscul Dis"},{"key":"3375_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-021-02489-x","volume":"21","author":"Y Nishiguchi","year":"2021","unstructured":"Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021;21:1\u20136.","journal-title":"BMC Neurol"},{"key":"3375_CR23","first-page":"16","volume":"2","author":"PY Sansen","year":"2021","unstructured":"Sansen PY, Calaras E, Weynants N, Glorieux P. Miller-Fisher Syndrome following the first dose of Comirnaty (Pfizer COVID-19 vaccination). J Med Case Rep Case Series. 2021;2:16.","journal-title":"J Med Case Rep Case Series"},{"key":"3375_CR24","doi-asserted-by":"publisher","unstructured":"Chen B, Lopez S, Eggenberger E. Miller Fisher syndrome after Pfizer BioNTech vaccine booster responsive to intravenous Ig treatment. BMJ Case Rep. 2022;15(11):e251361. https:\/\/doi.org\/10.1136\/bcr-2022-251361.","DOI":"10.1136\/bcr-2022-251361"},{"issue":"1","key":"3375_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/01.ccm.0000807236.72940.f2","volume":"50","author":"N Kaur","year":"2022","unstructured":"Kaur N, Mayo M, Torres M. 228: Miller-Fisher syndrome and Covid vaccination. Crit Care Med. 2022;50(1):99.","journal-title":"Crit Care Med"},{"key":"3375_CR26","doi-asserted-by":"publisher","unstructured":"Kim JE, Min YG, Shin JY, Kwon YN, Bae JS, Sung JJ, Hong YH. Guillain-Barr\u00e9 Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases. Front Neurol. 2022;12:820723. https:\/\/doi.org\/10.3389\/fneur.2021.820723.","DOI":"10.3389\/fneur.2021.820723"},{"issue":"6","key":"3375_CR27","doi-asserted-by":"publisher","first-page":"2125753","DOI":"10.1080\/21645515.2022.2125753","volume":"18","author":"H Liang","year":"2022","unstructured":"Liang H, Cao Y, Zhong W, Ma Z, Liu J, Chen H. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome following inactivated COVID-19 vaccine: case report and scope review. Hum Vaccin Immunother. 2022;18(6):2125753.","journal-title":"Hum Vaccin Immunother"},{"issue":"22","key":"3375_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1212\/WNL.0000000000011881","volume":"96","author":"AMM Loza","year":"2021","unstructured":"Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96(22):1052\u20134.","journal-title":"Neurology"},{"issue":"1","key":"3375_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12883-022-02838-4","volume":"22","author":"K Nanatsue","year":"2022","unstructured":"Nanatsue K, Takahashi M, Itaya S, Abe K, Inaba A. A case of Miller Fisher syndrome with delayed onset peripheral facial nerve palsy after COVID-19 vaccination: a case report. BMC Neurol. 2022;22(1):309.","journal-title":"BMC Neurol"},{"issue":"1","key":"3375_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13256-022-03592-4","volume":"16","author":"FJC Pirola","year":"2022","unstructured":"Pirola FJC, Santos BAM, Sapienza GF, Cetrangolo LY, Geranutti CHWG, de Aguiar PHP. Miller-Fisher syndrome after first dose of Oxford\/AstraZeneca coronavirus disease 2019 vaccine: a case report. J Med Case Reports. 2022;16(1):437.","journal-title":"J Med Case Reports"},{"issue":"20","key":"3375_CR31","doi-asserted-by":"publisher","first-page":"e29333","DOI":"10.1097\/MD.0000000000029333","volume":"101","author":"AR Siddiqi","year":"2022","unstructured":"Siddiqi AR, Khan T, Tahir MJ, Asghar MS, Islam MS, Yousaf Z. Miller Fisher syndrome after COVID-19 vaccination: case report and review of literature. Medicine. 2022;101(20):e29333.","journal-title":"Medicine"},{"issue":"7","key":"3375_CR32","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2169\/internalmedicine.8851-21","volume":"61","author":"M Yamakawa","year":"2022","unstructured":"Yamakawa M, Nakahara K, Nakanishi T, Nomura T, Ueda M. Miller Fisher syndrome following vaccination against SARS-CoV-2. Intern Med. 2022;61(7):1067\u20139.","journal-title":"Intern Med"},{"issue":"17","key":"3375_CR33","doi-asserted-by":"publisher","first-page":"20939","DOI":"10.1007\/s11356-021-13233-w","volume":"28","author":"Z Li","year":"2021","unstructured":"Li Z, Li X, Shen J, Chan MTV, Wu WKK. Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review. Environ Sci Pollut Res Int. 2021;28(17):20939\u201344.","journal-title":"Environ Sci Pollut Res Int"},{"key":"3375_CR34","unstructured":"Rocha Cabrero F ME. Miller Fisher Syndrome: Treasure Island (FL): StatPearls; Publishing; 2022 [Cited 10 Feb 2023]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507717\/."},{"issue":"7830","key":"3375_CR35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594\u20139.","journal-title":"Nature"},{"issue":"4","key":"3375_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, Li XM, Shuai ZW, Ye DQ, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386\u2013401.","journal-title":"Immunology"},{"issue":"8","key":"3375_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol. 2021;21(8):475\u201384.","journal-title":"Nat Rev Immunol"},{"key":"3375_CR38","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2147\/NDT.S377357","volume":"18","author":"J Finsterer","year":"2022","unstructured":"Finsterer J, Scorza FA. Neurological Side Effects of SARS-CoV-2 Vaccinations are Not Uncommon but Frequently Ignored [Letter]. Neuropsychiatr Dis Treat. 2022;18:1273\u20135.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"3375_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ane.13550","volume":"145","author":"J Finsterer","year":"2022","unstructured":"Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022;145(1):5\u20139.","journal-title":"Acta Neurol Scand"},{"key":"3375_CR40","unstructured":"COVID-19 vaccine contraindications and precautions: Autralian Government Department of Health and Aged Care; [Updated 1 Dec 2022. Available from: https:\/\/www.health.gov.au\/our-work\/covid-19-vaccines\/advice-for-providers\/clinical-guidance\/contraindications-and-precautions."},{"issue":"6","key":"3375_CR41","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/ene.12983","volume":"23","author":"Y Sekiguchi","year":"2016","unstructured":"Sekiguchi Y, Mori M, Misawa S, Sawai S, Yuki N, Beppu M, et al. How often and when Fisher syndrome is overlapped by Guillain-Barr\u00e9 syndrome or Bickerstaff brainstem encephalitis? Eur J Neurol. 2016;23(6):1058\u201363.","journal-title":"Eur J Neurol"},{"issue":"1","key":"3375_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/jnnp.2008.154351","volume":"80","author":"K Funakoshi","year":"2009","unstructured":"Funakoshi K, Kuwabara S, Odaka M, Hirata K, Yuki N. Clinical predictors of mechanical ventilation in Fisher\/Guillain\u2013Barr\u00e9 overlap syndrome. J Neurol Neurosurg Psychiatry. 2009;80(1):60\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3375_CR43","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jns.12238","volume":"22","author":"C Verboon","year":"2017","unstructured":"Verboon C, van Berghem H, van Doorn PA, Ruts L, Jacobs BC. Prediction of disease progression in Miller Fisher and overlap syndromes. J Peripher Nerv Syst. 2017;22(4):446\u201350.","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"3375_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1468-1331.2011.03445.x","volume":"19","author":"Z Ar\u00e1nyi","year":"2012","unstructured":"Ar\u00e1nyi Z, Kov\u00e1cs T, Sipos I, Bereczki D. Miller Fisher syndrome: brief overview and update with a focus on electrophysiological findings. Eur J Neurol. 2012;19(1):15-e3.","journal-title":"Eur J Neurol"},{"issue":"10","key":"3375_CR45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/glycob\/cwab032","volume":"31","author":"X-L Sun","year":"2021","unstructured":"Sun X-L. The role of cell surface sialic acids for SARS-CoV-2 infection. Glycobiology. 2021;31(10):1245\u201353.","journal-title":"Glycobiology"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03375-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03375-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T06:55:00Z","timestamp":1703228100000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03375-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3375"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03375-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"9 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}